Actos

In August 2011, the Food and Drug Administration approved a new warning that the diabetes drug Actos could increase a patient’s risk of developing bladder cancer. According to a five-year study of Actos, patients taking the drug for more than one year were 40% more likely to develop bladder cancer.

A study conducted in France also showed that the use of Actos increased a patient’s risk of bladder cancer compared to other diabetes drugs, regardless of how long they had taken the drug. In response to this data, health officials in France and Germany halted sales of Actos due the risk of side effects.

Although the FDA has not announced plans to issue an Actos recall, the agency has warned doctors not to prescribe the drug to patients with bladder cancer or with a history of the disease. The agency also warned about prescribing other drugs that contain pioglitazone—the active ingredient in Actos—including Actoplus Met, Actoplus Met XR and Duetact.

Some legal experts have estimated that Takeda Pharmaceuticals—the manufacturer of Actos—could face thousands of lawsuits from patients who developed bladder cancer after taking the diabetes drug. Actos lawyers say that they have already been in contact with hundreds of possible clients who are interested in filing a lawsuit.

If you or a loved one developed bladder cancer, congestive heart failure or other side effects after using Actos, you may qualify to file a lawsuit. For a free legal consultation, contact the lawyers at Hissey Kientz, LLP by calling toll-free at 1-866-275-4454, or by filling out the free case evaluation form located on this page.

I am currently represented by an attorney
*Required fields